by Clinical Neuropsychologist | Friday, January 3, 2025 | Dementia
Abstract Background Cerebrovascular alterations and innate immune activation are key features of Alzheimer’s disease (AD). However, the mechanisms that link blood-brain barrier disruption to neurodegeneration are poorly understood and well-defined druggable targets at...
by Clinical Neuropsychologist | Friday, January 3, 2025 | Dementia
Abstract Background MicroRNAs have been linked to dementia. However, understanding their relation to cognition in the general population is required to determine their potential use for the detection and prevention of age-associated cognitive decline and preclinical...
by Clinical Neuropsychologist | Thursday, January 2, 2025 | Dementia
Abstract INTRODUCTION Whole genome methylation sequencing (WGMS) in blood identifies differential DNA methylation in persons with late-onset dementia due to Alzheimer’s disease (AD) but has not been tested in persons with mild cognitive impairment (MCI). METHODS...
by Clinical Neuropsychologist | Wednesday, January 1, 2025 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | January 1, 2025 Wiley: Alzheimer’s & Dementia:...
by Clinical Neuropsychologist | Tuesday, December 31, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD), primary age-related tauopathy (PART), and chronic traumatic encephalopathy (CTE) all feature hyperphosphorylated tau (p-tau)–immunoreactive neurofibrillary degeneration, but differ in neuroanatomical distribution...
